JO
ATNM icon

John Overdeck’s Actinium Pharmaceuticals ATNM Stock Holding History

John Overdeck’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
259,179
-77,989
-23% -$90.1K ﹤0.01% 4631
2026
Q1 		$336K Buy
337,168
+127,476
+61% +$152K ﹤0.01% 3997
2025
Q4 		$285K Sell
209,692
-24,601
-11% -$35.9K ﹤0.01% 3600
2025
Q3 		$375K Buy
234,293
+187,748
+403% +$306K ﹤0.01% 3119
2025
Q2 		$65.2K Buy
+46,545
New +$69.7K ﹤0.01% 3041
2023
Q3 		– Sell
-19,468
Closed -$144K – 2947
2023
Q2 		$144K Sell
19,468
-26,075
-57% -$222K ﹤0.01% 2703
2023
Q1 		$430K Sell
45,543
-167,777
-79% -$1.77M ﹤0.01% 2274
2022
Q4 		$2.27M Buy
213,320
+197,494
+1,248% +$2M 0.01% 1264
2022
Q3 		$117K Sell
15,826
-41,392
-72% -$257K ﹤0.01% 2206
2022
Q2 		$275K Buy
+57,218
New +$325K ﹤0.01% 2059

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's ATNM Position: Q2 2026 in Review

John Overdeck reduced its Actinium Pharmaceuticals (ATNM) stake by 23% in Q2 2026, selling an estimated $90.1K and leaving 259,179 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #4631.

John Overdeck first reported a position in ATNM in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.27M in Q4 2022. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • John Overdeck held 259,179 shares of Actinium Pharmaceuticals worth $254K as of Q2 2026.
  • John Overdeck sold 77,989 Actinium Pharmaceuticals shares in Q2 2026, an estimated $90.1K.
  • Actinium Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4631 holding.
  • John Overdeck first reported a position in Actinium Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • John Overdeck's Actinium Pharmaceuticals position peaked at $2.27M in Q4 2022.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.